CannaPharmaRX, Inc.
CPMD
$0.00
$0.002.70%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.09% | 404.62% | 5,175.97% | 4,278.29% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.09% | 404.62% | 5,175.97% | 4,278.29% | -- |
| Cost of Revenue | -0.12% | 201.06% | 362.78% | 376.62% | 5,624.09% |
| Gross Profit | 18.62% | -148.51% | -232.55% | -247.92% | -4,374.09% |
| SG&A Expenses | 28.44% | 22,132.35% | -3.37% | -44.91% | -45.70% |
| Depreciation & Amortization | -- | -880.90% | -228.95% | -129.81% | -100.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.35% | 223.96% | 208.47% | 123.53% | 182.57% |
| Operating Income | 9.60% | -180.24% | -125.74% | -67.83% | -130.51% |
| Income Before Tax | -12.37% | -630.59% | -1,001.72% | 116.92% | -368.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.37% | -630.59% | -1,001.72% | 116.92% | -368.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.37% | -630.59% | -1,001.72% | 116.92% | -368.56% |
| EBIT | 9.60% | -180.24% | -125.74% | -67.83% | -130.51% |
| EBITDA | 58.99% | -155.68% | -216.36% | -105.72% | -193.62% |
| EPS Basic | 45.42% | -179.49% | -37.70% | 108.78% | -477.78% |
| Normalized Basic EPS | 66.84% | 54.30% | 67.88% | 108.99% | -187.88% |
| EPS Diluted | 45.42% | -179.49% | -37.70% | 108.78% | -477.78% |
| Normalized Diluted EPS | 66.84% | 54.30% | 67.88% | 108.99% | -187.88% |
| Average Basic Shares Outstanding | 13.55% | 30.64% | 59.53% | 103.05% | 87.39% |
| Average Diluted Shares Outstanding | 13.55% | 30.64% | 59.53% | 103.05% | 87.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |